Serina Therapeutics (SER) Regulatory Update

Material Event: On November 3, 2025, Serina Therapeutics, Inc. announced a significant regulatory setback.

• The U.S. FDA placed a clinical hold on the Investigational New Drug (IND) application for SER-252.
• SER-252 is the Company’s lead development program targeting advanced Parkinson’s disease.

This development directly impacts the timeline and viability of the Company’s primary pipeline asset. Investors should review Exhibit 99.1 for the full press release details regarding the reason for the hold.

__Critical Item